TG Therapeutics

a commercial stage biopharmaceutical company

TGTX Nasdaq ISIN US88322Q1085 SEC CIK 1001316 LEI 529900X21UKABN9NJ529
Follow TG Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $259.9M +60.7% vs same quarter last year
Net income $55.5M −85.8% vs same quarter last year
EPS, diluted $0.35 −85.6% vs same quarter last year
Operating cash flow $45.2M +295.3% vs same quarter last year
Revenue by quarter
$108.2M
$120.9M
$141.1M
$161.7M
$192.6M
$204.9M
$240.3M
$259.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$500M−$250M$0$250M$500M$750MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$616.3M$447.2M
FY24$329M$23.4M
FY23$233.7M$12.7M
FY22$2.8M−$198.3M
FY21$6.7M−$348.1M
FY20$152K−$279.4M
FY19$152K−$172.9M
FY18$152K−$173.5M
FY17$152K−$118.5M
FY16$152K−$78.3M
FY15-−$62.9M
FY14-−$55.8M
FY13-−$20.5M
FY12-−$18.1M
FY11-−$853.1K
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200000%−150000%−100000%−50000%0%50000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2583.7%20%72.6%
FY2488.3%12.7%7.1%
FY2394%8.8%5.4%
FY2290.5%−7839%−7120.3%
FY2188.2%−5154.3%−5204.1%
FY20-−179996.1%−183803.3%
FY19-−111220.4%−113730.9%
FY18-−114736.8%−114132.9%
FY17-−78100%−77944.7%
FY16-−51953.3%−51482.2%
FY15---
FY14---
FY13---
FY12---
FY11---
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$25M
FY24−$40.6M
FY23−$31.4M
FY22−$176.2M
FY21−$296M
FY20−$214.9M
FY19−$132.9M
FY18−$129M
FY17−$93.8M
FY16−$61.9M
FY15−$44.7M
FY14−$35.1M
FY13−$10.7M
FY12−$5.2M
FY11−$86.6K
Returned to shareholdersDividends paid and shares bought back
$0$50K$100K$150KFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15$0
FY14$0
FY13$149.8K
FY12$84.5K
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • TG Therapeutics
  • Healthcare median
−200000%−150000%−100000%−50000%0%50000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearTG TherapeuticsHealthcare median
FY2572.6%−30.6%
FY247.1%−47%
FY235.4%−58%
FY22−7120.3%−80.4%
FY21−5204.1%−71.9%
FY20−183803.3%−62.2%
FY19−113730.9%−46.3%
FY18−114132.9%−49.6%
FY17−77944.7%−45.9%
FY16−51482.2%−36%
FY15-−38.4%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%